Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294705 · ClinicalTrials.gov registry record
The Autism Biomarkers Consortium for Clinical Trials: Confirmation Study
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 565
- Enrollment target
NCT05294705: Completed study, sponsored by Yale University.
NCT05294705 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 565 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05294705 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 565 participants
- Enrollment target
Study Summary
This is a multicenter longitudinal study that aims to validate a set of measures that were previously identified as promising candidate biomarkers and/or sensitive and reliable objective measures of social function in ASD for potential use in clinical trials. The confirmation study will repeat the data collection and analysis protocols from the original ABC-CT study. This confirmation study will recruit 200 ASD and 200 TD comparison participants who are 6-11 years old, matching the overall sample size but providing a larger normative reference sample and greater statistical power for group comparisons.
Primary Outcome
The N170 Latency to Upright Human Faces (N170 latency) is a scalp recorded EEG event-related potential (ERP) component elicited by perception of the upright human face. Recorded over the posterior-temporal right hemisphere, the latency (or speed) of the peak of the N170 ERP component occurs at approximately 200 msec in children aged 6 to 11 years of age.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2025-08-31 |
What the finished NCT05294705 record still lists
NCT05294705 is an observational study that tracks outcomes without assigning an intervention. The registered 565 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05294705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05294705 about?
NCT05294705 is a clinical study titled "The Autism Biomarkers Consortium for Clinical Trials: Confirmation Study". This is a multicenter longitudinal study that aims to validate a set of measures that were previously identified as promising candidate biomarkers and/or sensitive and reliable objective measures of social function in ASD for potential use in clinical trials. The confirmation study will repeat the d...
What is the current status of trial NCT05294705?
This trial is currently completed. The enrollment target is 565 participants. The study started on 2022-04-11. Estimated completion is 2025-08-31.
Who is sponsoring clinical trial NCT05294705?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI